DE60238471D1 - Proteosom-liposaccharid-vakzine-adjuvans - Google Patents
Proteosom-liposaccharid-vakzine-adjuvansInfo
- Publication number
- DE60238471D1 DE60238471D1 DE60238471T DE60238471T DE60238471D1 DE 60238471 D1 DE60238471 D1 DE 60238471D1 DE 60238471 T DE60238471 T DE 60238471T DE 60238471 T DE60238471 T DE 60238471T DE 60238471 D1 DE60238471 D1 DE 60238471D1
- Authority
- DE
- Germany
- Prior art keywords
- liposaccharide
- proteosome
- variety
- vaccine adjuvant
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27423201P | 2001-03-09 | 2001-03-09 | |
US32729701P | 2001-10-09 | 2001-10-09 | |
PCT/US2002/007108 WO2002072012A2 (en) | 2001-03-09 | 2002-03-11 | A novel proteosome-liposaccharide vaccine adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60238471D1 true DE60238471D1 (de) | 2011-01-13 |
Family
ID=26956684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60238471T Expired - Lifetime DE60238471D1 (de) | 2001-03-09 | 2002-03-11 | Proteosom-liposaccharid-vakzine-adjuvans |
Country Status (9)
Country | Link |
---|---|
US (2) | US7524509B2 (de) |
EP (1) | EP1372706B1 (de) |
JP (2) | JP4137640B2 (de) |
AT (1) | ATE489968T1 (de) |
AU (1) | AU2002245636B2 (de) |
CA (1) | CA2438425C (de) |
DE (1) | DE60238471D1 (de) |
MX (1) | MXPA03008154A (de) |
WO (1) | WO2002072012A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22983A1 (es) * | 2002-05-08 | 2004-09-09 | Inst Finlay | Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
EP1622641A2 (de) * | 2003-05-05 | 2006-02-08 | ID Biomedical Corporation of Quebec | Impfungen gegen infektionskrankheiten unter verwendungen proteosomen |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
EP1667713A1 (de) * | 2003-09-15 | 2006-06-14 | ID Biomedical Corporation of Quebec | Masern-untereinheit-vakzine |
US8173140B2 (en) * | 2003-10-22 | 2012-05-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
CU23420A1 (es) * | 2003-12-30 | 2009-09-08 | Univ De Cambridge | Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes |
JP5274011B2 (ja) * | 2004-06-25 | 2013-08-28 | アイディー バイオメディカル コーポレイション オブ ケベック | 神経障害を治療するための組成物および方法 |
US20060286124A1 (en) * | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
LT2351772T (lt) | 2005-02-18 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli |
DK2368572T3 (da) | 2005-11-04 | 2020-05-25 | Seqirus Uk Ltd | Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
PL2054431T3 (pl) | 2006-06-09 | 2012-07-31 | Novartis Ag | Konformery adhezyn bakteryjnych |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
WO2009062132A2 (en) | 2007-11-09 | 2009-05-14 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
SI2222710T1 (sl) | 2007-12-24 | 2016-11-30 | Id Biomedical Corporation Of Quebec | Rekombinatni RSV antigeni |
WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
US20110171259A1 (en) | 2008-09-05 | 2011-07-14 | Martin Gagne | Novel Compositions and Adjuvants |
JP2012524910A (ja) * | 2009-04-23 | 2012-10-18 | カリフォルニア インスティチュート オブ テクノロジー | 免疫調節物質の同定方法及びシステム |
WO2010149743A2 (en) | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
CA2766211A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
EP3988115A3 (de) | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung |
WO2011106525A2 (en) | 2010-02-26 | 2011-09-01 | The Brigham And Women's Hospital, Inc. | Methods of treating cerebral amyloid angiopathy |
ES2694100T3 (es) | 2010-04-07 | 2018-12-18 | California Institute Of Technology | Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados |
JP2013532008A (ja) | 2010-05-28 | 2013-08-15 | テトリス オンライン インコーポレイテッド | 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
CA2815275C (en) | 2010-10-27 | 2023-09-19 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions derived from shigella |
WO2013009945A1 (en) | 2011-07-12 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
EP3608332B1 (de) | 2013-03-15 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Impfstoff gegen humanes rhinovirus |
JP2016521284A (ja) | 2013-05-10 | 2016-07-21 | カリフォルニア インスティチュート オブ テクノロジー | 大腸ガンのプロバイオティクスによる防止および処置 |
BE1022008B1 (fr) | 2013-08-05 | 2016-02-03 | Glaxosmithkline Biologicals S.A. | Compositions immunogenes combinees |
CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
CA2977493C (en) | 2015-03-03 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Display platform from bacterial spore coat proteins |
WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
CA2997211A1 (en) | 2015-08-19 | 2017-02-23 | President And Fellows Of Harvard College | Lipidated psa compositions and methods |
WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
WO2023114727A1 (en) | 2021-12-13 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage lambda-vaccine system |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08508247A (ja) * | 1993-03-11 | 1996-09-03 | セクレテック,インク. | 粘膜表面への免疫原の輸送における重合的粘膜付着体 |
CA2172507C (en) | 1993-10-22 | 2008-12-02 | Jeffrey L. Cleland | Methods and compositions for microencapsulation of antigens for use as vaccines |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
CN1211192A (zh) * | 1995-09-18 | 1999-03-17 | 美国陆军医疗材料研究指挥部 | 生产非共价复合的多价蛋白体亚基疫苗的改进方法 |
EP0929678A2 (de) | 1996-07-10 | 1999-07-21 | ID Biomedical Corporation of Maryland | Protein- und peptid-impfstoffe und induzierung der immunität in der schleimhaut |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
ATE331530T1 (de) * | 2000-02-15 | 2006-07-15 | Id Biomedical Corp Quebec | Proteasom-influenzavirus-impfstoffzusammensetzu g |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
EP1667713A1 (de) * | 2003-09-15 | 2006-06-14 | ID Biomedical Corporation of Quebec | Masern-untereinheit-vakzine |
US8173140B2 (en) * | 2003-10-22 | 2012-05-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
US20060286124A1 (en) * | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
US20060228233A1 (en) * | 2005-03-31 | 2006-10-12 | Arimitsu Of North America, Inc. | Pump and motor assembly |
-
2002
- 2002-03-11 AU AU2002245636A patent/AU2002245636B2/en not_active Expired
- 2002-03-11 AT AT02713807T patent/ATE489968T1/de not_active IP Right Cessation
- 2002-03-11 CA CA2438425A patent/CA2438425C/en not_active Expired - Lifetime
- 2002-03-11 US US10/094,424 patent/US7524509B2/en not_active Expired - Lifetime
- 2002-03-11 MX MXPA03008154A patent/MXPA03008154A/es not_active Application Discontinuation
- 2002-03-11 DE DE60238471T patent/DE60238471D1/de not_active Expired - Lifetime
- 2002-03-11 WO PCT/US2002/007108 patent/WO2002072012A2/en active IP Right Grant
- 2002-03-11 EP EP02713807A patent/EP1372706B1/de not_active Expired - Lifetime
- 2002-03-11 JP JP2002570972A patent/JP4137640B2/ja not_active Expired - Lifetime
-
2006
- 2006-11-13 JP JP2006307227A patent/JP2007031457A/ja active Pending
-
2009
- 2009-03-30 US US12/414,497 patent/US20090252762A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE489968T1 (de) | 2010-12-15 |
CA2438425A1 (en) | 2002-09-19 |
JP2007031457A (ja) | 2007-02-08 |
WO2002072012A3 (en) | 2003-02-27 |
WO2002072012A2 (en) | 2002-09-19 |
CA2438425C (en) | 2012-05-01 |
JP2004521925A (ja) | 2004-07-22 |
US20090252762A1 (en) | 2009-10-08 |
JP4137640B2 (ja) | 2008-08-20 |
EP1372706B1 (de) | 2010-12-01 |
US20030044425A1 (en) | 2003-03-06 |
EP1372706A4 (de) | 2004-08-25 |
AU2002245636B2 (en) | 2004-10-14 |
US7524509B2 (en) | 2009-04-28 |
EP1372706A2 (de) | 2004-01-02 |
MXPA03008154A (es) | 2004-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60238471D1 (de) | Proteosom-liposaccharid-vakzine-adjuvans | |
EP1333858B8 (de) | Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung | |
AR022965A1 (es) | Vacuna | |
DK0764029T3 (da) | Proteinadjuvanser | |
ATE320493T1 (de) | Modifizierung des hepatitis b kernantigens | |
ATE529130T1 (de) | Trockenformulierung für transkutane immunisierung | |
IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
ATE326231T1 (de) | Mutierendes enterotoxin als nichttoxisches orales adjuvans | |
DE69943170D1 (de) | Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten | |
HUP0002475A2 (hu) | Módosított immunogén pneumolizinkészítmények mint vakcinák | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
NO331017B1 (no) | Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning. | |
AP2003002734A0 (en) | Purification of HBV antigens for use in vaccines. | |
WO2003089584A3 (en) | Use of parapox b2l protein to modify immune responses to administered antigens | |
EA200700496A1 (ru) | Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита | |
DE60218662D1 (de) | Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine | |
EP0694309A3 (de) | Vakzine, Antigene und Antikörper enthaltende Zusammensetzung für den Schutz und die Hemmung von durch Staphylococcus induzierten Infektionen | |
EP1438066A4 (de) | Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen | |
WO2003053338A3 (en) | Novel chimeric rev, tat, and nef antigens | |
WO2005009397A3 (en) | Human lymphocyte vaccine adjuvant | |
WO2003050135A3 (en) | Use a parapox b2l protein to modify immune responses to administered antigens | |
WO2001015727A3 (en) | Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof | |
WO2002060390A3 (en) | Induction of immune responses to isoaspartyl-modified antigens | |
DK0952771T3 (da) | Hidtil ukendte saponinpræparater og anvendelser deraf | |
WO2001040472A3 (en) | Streptococcus pneumoniae antigens |